Back to Journals » Journal of Asthma and Allergy » Volume 8

A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy

Authors Ciprandi G, Frati F

Received 2 February 2015

Accepted for publication 10 February 2015

Published 6 March 2015 Volume 2015:8 Pages 25—27

DOI https://doi.org/10.2147/JAA.S82077


Giorgio Ciprandi

Medicine Department, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy

After a century of allergen immunotherapy (AIT), for the first time, the Italian Agency for Drugs (AIFA [Agenzia italiana per il farmaco]) has just approved the full reimbursement (A class) for an AIT product, such as the 5-grass pollen tablet with the indication for treating allergic rhinitis (AR).
On the other hand, AR represents a relevant health issue as the worldwide prevalence is approximately 20%.1 AR is sustained by an IgE-mediated inflammatory reaction that in turn induces typical symptom occurrence. Allergic inflammation is promoted by an allergen-specific defect of T-regulatory cells and a Th2 polarization.2 This impaired immune response characterizes the two main peculiarities of allergic reaction: systemic IgE production and nasal eosinophil infiltrate.3 AR has also a significant social burden both in terms of high costs and individual complaints, mainly negatively affecting quality of life.


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]